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Abstract
Background: Interpreting large-scale studies from microarrays or next-generation sequencing for further experimental
testing remains one of the major challenges in quantitative biology. Combining expression with physical or genetic
interaction data has already been successfully applied to enhance knowledge from all types of high-throughput
studies. Yet, toolboxes for navigating and understanding even small gene or protein networks are poorly developed.
Results: We introduce two Cytoscape plug-ins, which support the generation and interpretation of experiment-based
interaction networks. The virtual pathway explorer viPEr creates so-called focus networks by joining a list of
experimentally determined genes with the interactome of a specific organism. viPEr calculates all paths
between two or more user-selected nodes, or explores the neighborhood of a single selected node. Numerical values
from expression studies assigned to the nodes serve to score identified paths. The pathway enrichment analysis tool
PEANuT annotates networks with pathway information from various sources and calculates enriched pathways
between a focus and a background network. Using time series expression data of atorvastatin treated primary
hepatocytes from six patients, we demonstrate the handling and applicability of viPEr and PEANuT. Based on
our investigations using viPEr and PEANuT, we suggest a role of the FoxA1/A2/A3 transcriptional network in
the cellular response to atorvastatin treatment. Moreover, we find an enrichment of metabolic and cancer
pathways in the Fox transcriptional network and demonstrate a patient-specific reaction to the drug.
Conclusions: The Cytoscape plug-in viPEr integrates –omics data with interactome data. It supports the interpretation
and navigation of large-scale datasets by creating focus networks, facilitating mechanistic predictions from –omics
studies. PEANuT provides an up-front method to identify underlying biological principles by calculating enriched
pathways in focus networks.
Keywords: Focus network, Disease state, Shortest path algorithm, Node neighborhood, Pathway enrichment
Background
The integration and biological interpretation of large-
scale datasets is currently one of the main challenges in
bioinformatics research. How can we extract meaningful
information from a list of differentially regulated genes?
One possibility to understand, how (co-)regulated genes
relate to each other is to view them in the context of their
physical, genetic or regulatory interactions: network-based
analysis using data from protein-protein or regulatory
interactions can open new perspectives for further experi-
mental studies.
Quantitative values from a functional screen or a list
of mutated genes identified in a cancer genomics study
can be used to generate sub-networks from a large, bio-
logical interaction network. These sub- or focus net-
works can be termed ‘disease’ or ‘state’ networks, as they
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describe the modules in the cell or the organism, which
are affected by a certain experimental condition or by a
particular disease. This approach has for instance been
employed by software like the database and web-tool
String [1] or the command-line based tool Netbox [2].
Focus networks can also be created based on a specific
biological question: how are two specific proteins - or
two groups of proteins - connected with each other?
This approach allows an even more biologically focused
view on the changes in the cellular network under differ-
ent conditions.
Focus networks allow us moreover to understand the
cross-talk between two molecules or pathways, which in
this context is defined by all paths between two proteins
or two groups of proteins.
Typically, some form of shortest-path algorithm like
Dijkstra’s algorithm [3] is used to create sub-networks
between two or more nodes. The numeric values from
functional genomics studies are used to score paths be-
tween two nodes. Methods like Pathfinder [4] or the
Reactome browser [5] have implemented this functional-
ity of connecting two molecules with each other within
a biological network. Both tools use numeric values also
to visualize regulatory changes that take place during
state changes of the cell/organism under study.
Focus networks can be further enriched using Gene
Ontology (GO) terms [6] or pathways from different
sources to provide additional functional information for
data interpretation. GO biological processes can also be
used to explore cross-connections between two or more
pathways and find missing pathway components. This
provides a more integrative view of a biological network.
The drug family of the statins is currently widely
used to lower cholesterol levels in the treatment of
hypercholesterolemia. Statins, which act as HMG-CoA
(3-hydroxy-3-methylglutaryl–coenzyme A) reductase
(HMGCR) inhibitors, prevent the production of chol-
esterol by inhibiting the biosynthesis of isoprenoids
and sterols in the mevalonate pathway [7]. However,
statins are known to have a variety of side effects, in-
cluding muscle adverse effects, liver damage, cognitive
impairment, cancer progression or diabetes mellitus
[8–11]. Functional genomics studies of statin-treated
cell systems indicate extensive changes of expression
levels upon drug treatment (see for instance [12–20]).
The detailed analysis of these transcriptional changes
should therefore lead to a better understanding of the
functions and pleiotropic effects of statins.
In this study, we re-analyzed the time-course expres-
sion data from atorvastatin-treated, primary human he-
patocytes from six different patients published in a
previous study [20]. We focused our analysis on deter-
mining the regulation of downstream genes from statin
drug targets as defined in STITCH [21]. We were
especially interested in addressing the following is-
sues: 1) How do statin targets and differentially regu-
lated genes relate to each other? 2) Which pathways
are affected upon statin treatment? 3) How does the
dynamics of the neighborhood of specific proteins change
after statin treatment?
In order to answer those questions, we have developed
two Cytoscape plug-ins that work together: viPEr, the
virtual Pathway Explorer, creates focus interaction net-
works by connecting two or more nodes with each
other. It applies user-provided expression data to score
paths between two nodes and thus limits the network to
functionally relevant paths. The Cytoscape plug-in
PEANuT (Pathway Enrichment ANalysis Tool) upgrades
interaction networks with pathway information and
identifies enriched pathways in focus networks.
We have applied our toolbox to re-analyze the expres-
sion data from atorvastatin-treated, primary human
hepatocytes and found that the transcription factors




viPEr was written in Java as a Cytoscape plug-in. The
basis of all functions is a recursive method, which iter-
ates through the members (nodes) of all paths emanat-
ing from a selected node. The step depth is influenced
by two parameters: 1) the maximum number of steps
allowed (set by the user). 2) the numerical values of the
nodes. We used the log2fold expression changes of ator-
vastatin treated primary hepatocytes described in [20] as
numerical values.
viPEr can be accessed under: http://sourceforge.net/
projects/viperplugin/
viPEr has three main search options:
1) ‘A to B’: ‘A to B’ connects two selected nodes with
each other. We refer to the paths between nodes A
and B as cross-talk. Mathematically, we define cross-
talk as all paths between two nodes (x1, x2), where a
single node in a path can only be passed once. The
result is a focus network, which is determined by
the maximum number of steps allowed between the
start and the target node. The search is stopped
when the target node is reached or the maximum
number of steps is exceeded. Only if the target has
been found, a path is stored, scored and displayed in
the results tab. The focus network is created based
on all nodes that are present in all stored paths.
The connecting edges are taken from the original
network. Therefore, all known interactions between
the subset of nodes are included in the newly created
focus network.
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Scoring of paths is done using the following
equation:
Score ¼ of differently regulated nodes ∈ path
pathlengthð Þ2
The p-values for discovered paths in focus networks
are calculated based on the cumulative probability of
the hypergeometric distribution to find k or more
differentially expressed genes in a path of length n.
2) ‘connecting in batch’: similarly to the ‘A to B’
search, two groups of nodes can be connected using
the ‘connection in batch’ function. For every node
in the start list A, the recursive search is computed
towards every node in the target list B. A results tab
with scored paths is not created in this case.
3) ‘environment search’: The third option is to
explore the regulated proximity of a single node
using the ‘environment search’. Just one starting
node is selected in this case. Mathematically, we
define the environment search as follows: a
network is calculated from all outgoing paths of
length l from x1, where every node is allowed to
be passed only once per path and all paths with at
least two consecutive node scores below threshold t
have been removed. The iteration through emanating
paths is carried out until the allowed maximum
search depth is reached. When exploring the
neighborhood of a single node, the numerical data
are used to select paths radiating from the selected
node. Paths, in which at least two consecutive nodes
are not differentially expressed, are removed from the
resulting neighbor focus network. Thus, only paths
that contain differentially regulated nodes are
considered for the environment search, though
single unregulated linker nodes are allowed. The
resulting network is referred to as a neighbor
focus network.
Using viPEr
Starting from any existing network supplemented with
expression data, the user has to select the attribute field
containing the expression information. A slider is auto-
matically set to the respective range of expression values.
After adjusting the slider to the desired expression range,
different options are available in the workflow (see Fig. 1).
1) ‘A to B’
This function executes the path search algorithm
between two selected nodes. The result is a focus
network of all identified paths of a certain length
between two nodes. The user selects the length
(step-size) of the calculated paths. All interconnecting
edges are added to the focus network. A result list,
which includes every discovered path between the
nodes, is located on the right side of the screen. This
list shows all paths, their respective members and the
assigned score as described above. The score can be
used to further reduce the focus network or simply to
visualize specific paths.
2) ‘connecting in batch’
Two groups of nodes can be connected in the
‘connecting in batch’ function of viPEr. The same
algorithm is used as in the ‘A to B’ search, except
that all paths between all members of a start list and
a target list are computed. This algorithm can be
applied to detect cross talk between two pathways,
two protein complexes or two hit lists from different
experiments. Three buttons have to be used for the
‘connecting in batch’ search: 1) a start protein list
has to be defined by selecting all starting nodes and
pressing the ‘select start protein list’; 2) the target
protein list has to be selected accordingly and
confirmed by pressing the ‘select target protein
list’ button; 3) the button ‘start connection in
batch’ executes the search.
3) ‘environment search’
In case only a single protein of interest exists, the
algorithm can be used to observe the dynamics of
expression in the environment of this protein
using the ‘environment search’. A single node is
selected and the search is executed with the button
‘environment search’. All regulated nodes within a
certain step size of the selected protein give rise to the
neighbor focus network.
PEANuT
PEANuT (Pathway Enrichment ANalysis Tool) is a
Cytoscape plug-in designed to annotate protein interaction
networks with biological pathway information and to iden-
tify enriched pathways in focus networks. The interactome
of the organism denotes the background network. Next to
visualizing enriched pathways in the focus networks, the re-
sults can be exported as a tab delimited file.
PEANuT can be accessed under: http://sourceforge.net/
projects/peanut-cyto and was implemented in Java.
The user can choose between the three databases
ConsensusPathDB (http://consensuspathdb.org/, [22]),
Pathway Commons (http://www.pathwaycommons.org/,
[23]) and Wikipathways (http://www.wikipathways.org/
[24]) to annotate the network. While ConsensusPathDB
requires Entrez gene IDs as input, Pathway Commons
and Wikipathways require UniProt accession numbers.
Annotation of nodes with these IDs can be done within
Cytoscape using for instance the plug-in CyThesaurus [25].
ConsensusPathDB and Pathway Commons contain
pathway data collected from publicly available pathway
databases (e.g., Reactome [26], KEGG [27]; see the
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respective homepages for more information). WikiPath-
ways is a database based on the ‘wiki principle’ and pro-
vides an open platform dedicated to collaborative
registering, reviewing and curation of biological pathways.
While Pathway Commons and WikiPathways work
with a wide variety of organisms, ConsensusPathDB is
specialized on human, mouse and yeast pathways. When
the user chooses to annotate his network of interest with
ConsensusPathDB data, he can additionally import di-
rected interactions from KEGG to increase the amount
of vertex degrees, enabling more complex path searches
using viPEr.
Information from Pathway Commons is accessed over
their web service. Flat files from the ConsensusPathDB
and WikiPathways webpages are downloaded via the
Apache Commons IO library (http://commons.apache.org/
proper/commons-io/) and Cytoscape internal downloader
classes.
Once downloaded, ConsensusPathDB and WikiPathways
can be used offline, while Pathway Commons requires
internet access. Network annotation with Pathway
Commons is slower, as it depends on the load and
availability of the host server, as well as internet con-
nection speed.
The probability value for the pathway enrichment in
the focus network is determined using the Apache
Commons Math library (http://commons.apache.org/
proper/commons-math/) to calculate the cumulative
probability of a hypergeometric distribution. Multiple test-
ing correction is achieved by applying either Bonferroni
[28] or Benjamini-Hochberg [29] correction.
PEANuT has three sub-menus:
1) ‘find pathways’: the find pathways sub-menu
annotates the networks in Cytoscape with pathway
data. Networks can be labeled using more than one
pathway resource by re-using the sub-menu with
different pathway selections.
2) ‘show pathway statistics’: the ‘show pathway
statistics’ sub-menu calculates enriched pathways in
a selected focus network. The user has to select the
focus network of interest, the background network
and choose a p-value cut-off. Enriched pathways can
be selected for visualization and downloaded as a
tab-delimited file.
3) ‘download/update dependencies’: this sub-menu is
used to download pathway information for network
annotation. It needs to be run before using PEANuT
the first time and should be run regularly to update
pathway information.
Using PEANuT
After installing PEANuT in Cytoscape by placing the
plug-in in the Cytoscape plug-in folder, the tool can be
Fig. 1 Workflow for creating focus networks. Workflow of viPEr in creating focus networks between two nodes/two groups of nodes, or in
exploring the neighborhood of a single node of interest. The user must select two nodes or group of nodes for creating a focus network. A
single node is selected when exploring the neighborhood. Numerical data (for instance from an expression screen) must be added to the
network for scoring paths of a focus network and for creating a neighbor focus network from a single node. In both cases, the user selects the
search depth. After creating the focus network, the network can for instance be explored by using and visualizing GO-terms. PEANuT is used to
find and visualize enriched pathways
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accessed via the plug-in menu. The sub-menus are used
as follows:
1) ‘find pathways’
This sub-menu allows the user to start the software
and annotate the network(s) of choice with pathway
data. In a simple dialog the user can select between
three different databases: ConsensusPathDB, Pathway
Commons or WikiPathways. The user can select
different options for each database depending on
preferences (such as import of directed interactions
from KEGG). Annotating the network with more than
one database is possible by subsequently re-running
this sub-menu with another selected database.
2) ‘show pathway statistics’
When the user has finished annotating the network,
clicking on the ‘show pathway statistics’ sub-menu
will invoke a table, two combo boxes, two text fields
and several buttons. In one of the text fields the user
can select the p-value cut-off for the enrichment
calculations. The combo boxes permit the user to
select the focus and background network. Once
the results have been calculated the user can export
the results as a tab delimited file or search the table
for pathways via the text box. The user can select each
pathway and highlight the members of the pathways
in the focus network by clicking on ‘select’.
3) ‘download/update dependencies’
In this sub-menu, dependencies can be used to
download/update information from ConsensusPathDB
and WikiPathways. ‘download/update dependencies’
needs to be executed when first using the plug-in. It is
good practice to refresh the dependencies from time to
time by clicking on the ‘download all’ button.
For more information on how to use PEANuT,
see our wiki http://sourceforge.net/p/peanut-cyto/
wiki/Home/.
Analysis of expression data
Cluster analysis
We used preprocessed data from Schröder et al. [20],
which have already been normalized and filtered and re-
peated the clustering step described in the original pub-
lication. The patient data used here were part of a large-
scale study originally published in [20] and deposited at
the Gene Expression Ominbus [30] resource (Accession
number GSE29868). Tissues and corresponding blood
samples of the original study were taken with written
informed consent from donors. The study was fur-
thermore approved by the ethics committees of the
medical faculties of the Charite, Humbold University
and University of Tübingen. Before clustering, the
data were log2 transformed and filtered for probes,
which were at least 1.7 fold differentially expressed in
at least 2 patients. With these 12,554 probes EDISA
clustering was performed, using the same parameters as in
Schröder et al. [20], with tG of 0.05 and tC of 0.25.
Creating the PP/TFG Interaction data
The basis for biologically meaningful network analysis is
a reliable interaction network with high confidence. To
accomplish this goal, we allowed only high confidence
interaction data. No predicted interactions or interac-
tions based on co-expression were included. As source
for protein-protein interactions, we chose Pathway
Commons [23] due to its large number of curated inter-
actions and the simple format, which can be directly
loaded in Cytoscape. Likewise, only experimentally
verified transcription factor – gene interactions from
TRANSFAC® were included in the network. Confidence
scores from TRANSFAC® were used to identify reliable
regulatory interactions.
GO and pathway enrichment of gene lists and networks
To analyze GO and pathway enrichment of focus net-
works, the official gene symbols (HGNC) were submit-
ted to DAVID [31]. Additionally, the GO annotation for
all nodes was added to the network via Cytoscapes’
built-in function.
Clustering of patient data using Cluster3
Cluster3 [32] was used to cluster patient data of the
FoxA1 neighbor focus network, as well as the 24 h time
point of the probe ID of all patients. Standard parameters
and average linkage clustering were chosen. The FoxA1
network was analyzed for presence (1) or absence (0) of a
node. In case of up-regulation, the value (2) was assigned,
while down-regulated nodes were assigned the value (−2)
(see Additional file 1: Table S12).
Results and discussion
Expression analysis of hepatocyte time-course experiment
In a first analysis, we found a total of 12.554 differen-
tially expressed probes in at least two patients irrespect-
ive of time-points (Additional file 1: Table S1). We
processed these genes with EDISA 3D clustering [33],
which resulted in 902 differentially regulated genes
(823 non-redundant genes) that were grouped into 24
clusters (Additional file 1: Tables S2 and S3). Further
analysis was performed with the non-redundant ver-
sion of this gene set.
GO and pathway enrichment
We submitted the processed gene list to DAVID [31]
for functional annotation and enrichment analysis
(Additional file 1: Tables S4 and S5). DAVID was
chosen for its extended functionality beyond enrichment
of Gene Ontology terms. Primarily, basic cellular and
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metabolic processes were enriched, such as amino acid or
nucleic acid metabolism. In addition, several pathways
and processes related to cellular cholesterol and lipid
-metabolism and -homeostasis were enriched. Based
on these results we could however not make any con-
clusions on the regulatory or transcriptional network
involved in atorvastatin response.
Focus network analysis
Next, we used focus network analysis to extract more in-
formation from the data. We decided to use the inter-
action network provided by Pathway Commons [23] as
the basic protein-protein interaction network, as it con-
tains information from more than one primary source
(including BioGRID, IntAct or Reactome). Given the
type of data in protein interaction databases, we rea-
soned that we additionally needed information on gene
regulatory relationships: which transcription factors are
able to regulate which gene set? We considered this in-
formation on transcription factor - gene interactions
(TFGI) as essential to identify the gene regulatory
networks that control the cellular response to statins
at a transcriptional level. We retrieved TFGIs from
TRANSFAC® and combined them with the protein-
protein interactions (PPIs) from Pathway Commons
to a single interaction network, which was used for
all further analysis steps (see Fig. 1).
Next, we extracted the top ten high confidence pri-
mary drug targets of atorvastatin from the STITCH
database [21] (Additional file 1: Table S6), all of which
were present in our interaction network. We used the
viPEr ‘connecting in batch’ function to connect the ten
atorvastatin targets with the 823 differentially regulated,
non-redundant genes we have identified with EDISA 3D
clustering, using a step-size of two. This functionality of
viPEr creates focus networks by searching for all paths
between two proteins or two groups of proteins, up to a
user-defined path length. The nodes are supplemented
with expression values. These weights on the nodes are
used to score all paths in the resulting focus networks.
The score of a path is dependent on its length and the
number of differentially regulated nodes it contains.
The resulting atorvastatin focus network contained
1107 nodes and 22029 edges (Additional file 2: Figure S1).
Of those, 21516 were PP interactions and 513 came from
TFG interactions. We next performed GO enrichment of
the atorvastatin focus network using DAVID (Additional
file 1: Table S7). We observed that with the proteins from
the focus network, we found more terms relating to regu-
latory functions, such as signaling or transcriptional con-
trol than with the 823 differentially expressed genes alone.
We searched for enriched pathways in the atorvastatin
focus network. To this end, we employed our pathway
enrichment tool PEANuT on the focus network, taking
the entire network of PPIs and TFGIs as a background.
Using ConsensusPathDB [22] as pathway resource,
PEANuT identified a total of 926 pathways, many of
which were redundant. Notably, again mainly signaling-,
as well as transcriptional regulation pathways were iden-
tified (Additional file 1: Table S8). We compared results
of PEANuT with pathway enrichment results from DA-
VID (Additional file 1: Table S9). Though different path-
way resources are available in DAVID, a similar set of
pathways was enriched. Those included growth receptor
signaling pathways such as the EGF-receptor-, VEGF-,
Insulin- and Ras-signaling pathways, Interleukin signal-
ing pathways, as well as cancer pathways. Due to the
availability of the pathway interaction database (PID,
[34]) of the ConsensusPathDB resource, however, more
transcription factor pathways were identified with
PEANuT.
Involvement of the FoxA transcription factors in
atorvastatin response
In the list of enriched pathways, our attention was
caught by the Forkhead box A transcription factor path-
ways. In adults, the Forkhead box A transcription factors
FoxA1, FoxA2 and FoxA3 are expressed in liver, pan-
creas and adipose tissue, where they regulate gene ex-
pression of metabolic genes [35]. Two direct targets of
atorvastatin are also targets of the FoxA transcription
factors: FoxA1 and FoxA2 regulate ApoB [36–38], while
Cyp3A4 is a target of FoxA3 [39]. Given our experimen-
tal set-up of atorvastatin-treatment of primary human
hepatocytes and the fact that atorvastatin is primarily
acting on cholesterol synthesis in the liver, we further
focused our analysis on these two transcriptional path-
ways. We created a viPEr focus network between the
primary atorvastatin target HMGCR and the three tran-
scription factors FoxA1, A2 and A3 (Fig. 2) starting from
the atorvastatin focus network with a maximal step size
of two, without considering a fold-change.
We visualized expression changes over time and pa-
tients in the HMGCR-FoxA1/2/3 focus network. We
first analyzed the expression changes over time from
patient 65 in the focus network (Fig. 2). HMGCR itself
is up-regulated at the first three time points, returning
to normal expression values at the later two time points.
Likewise, Cyp3A4 is up regulated at time points 6, 12
and 24, however becomes down regulated at 72 h.
Next, we were interested, whether the expression re-
sponse to atorvastatin was similar in the six different
patients and plotted HMGCR-FoxA1/2/3 focus networks
for each patient at 12 h after treatment (Additional
file 3: Figure S2). This representation of the data was
especially informative as it illustrated the obvious dif-
ferences in response to atorvastatin in the primary
hepatocytes from the six patients. We observed that
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Fig. 2 (See legend on next page.)
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only donors 62, 65 and 79 showed somewhat overlap-
ping regulatory responses at 12 h after treatment. The
expression pattern of patient 67 was in many cases
opposite to the first group (62, 65 and 79), while the
hepatocytes from patients 80 and 81 showed milder
responses to the drug.
Interpreting the HMGCR-FoxA1/2/3 focus network
The focus network of HMGCR and the FoxA transcrip-
tion factors can be divided in two parts (see Figs. 2
and 3). A small, tightly connected sub-cluster con-
tains small molecules, as well as metabolic genes,
while the larger sub-cluster contains signaling mole-
cules, as well as transcription factors. HMGCR is dir-
ectly connected to two proteins from this cluster: the
cAMP dependent protein kinase alpha, PRKACA and
Rho GTPase activating protein 1, ARHGAP1.
Especially FoxA1 is tightly integrated with other tran-
scription factors from the large sub-cluster, including
the transcription factors Sp1, Tp53, Fos, Jun or Brca1. It
also binds several transcriptional co-activators.
Note that HMGCR expression is not directly regulated
by any of the transcription factors in the network. The
connections between the FoxA proteins and HMGCR
are mostly due to transcriptional targets of the FoxA’s
interacting with PRKACA and ARHGAP1.
Interestingly, statins have been implicated to have a
preventive effect on different cancer types and to be
beneficial for the treatment of several cancer types,
among which are breast and prostate cancer [40–44].
Bcl2, a direct transcriptional target of FoxA1 [45], is
also a direct interactor of the HMGCR interacting kinase
PRKACA. Previous studies have shown that Bcl2 is
down-regulated in response to statin-induced apoptosis
([46]; for a review on the involvement of Bcl2 in statin-
response, see [47]); PRKACA has on the other hand
been implicated in statin-resistance of tumors by phos-
phorylating the pro-apoptotic protein Bad (Bcl2 associ-
ated death receptor), thus allowing anti-apoptotic
signaling [48].
In conclusion, cross-talk via PRKACA and ARHGAP1
is therefore one possible link between the mevalonate
pathway and the FoxA transcriptional network, which
could in part explain the effect of statins on apoptosis of
cancer cells.
Pathway enrichment analysis on focus networks using the
Cytoscape plug-in PEANuT
We performed pathway enrichment analysis using
PEANuT on the HMGCR-FoxA1/2/3 focus network
(Additional file 1: Table S10). Again, many signaling, as
well as metabolic pathways were enriched. In accordance
with previous reports on statin-sensitivity of cancer cells
[41, 42, 46, 49], several cancer pathways are enriched in
our focus network. In Fig. 3, we illustrate the usefulness
of PEANuT in visualizing components of enriched path-
ways in focus networks created with viPEr. We chose
to highlight the two cancer pathways ‘integrated
breast cancer’ (Wikipathways) and ‘prostate cancer’
(Wikipathways), as well as the pathway metabolism of
lipids and lipoproteins (Reactome) in the HMGCR-
FoxA1/2/3 focus network. Similar pathways were identi-
fied using DAVID (Additional file 1: Table S11).
Exploring the molecular environment of a node using viPEr
In a next analysis step, we used viPEr’s functionality
‘environment search’ to explore the neighborhood of a
single protein of interest. As a rule, only one linker
node without differential expression is allowed in the
‘environment search’. The user sets again the search
depth by defining the step size. All paths that lack
differentially expressed nodes are removed from the
resulting neighbor focus network.
We chose one of the Fox transcription factors, FoxA1,
as the start node and used a search depth of two. We
assumed that an environment search with FoxA1 might
shed light on the pathways and genes regulated by this
transcription factor during atorvastatin treatment. We
chose the 24 h time point for further analysis. Earlier
time points showed only few differentially expressed
genes for most of the patient samples. In later time
points, a considerable amount of genes was changed,
possibly due to secondary effects. Data from the six pa-
tients at time point 24 h are shown in Fig. 4.
The striking difference of patient 67 is again visible:
the environment search of FoxA1 under the chosen con-
ditions (2 steps, log2 fold change of at least 1.5) pro-
duced the largest network of all patients. Most proteins
in patient 67’s network are up regulated. Notably, the
central transcription factor Sp1 is up regulated, which is
potentially the cause of the strong effect we observed in
gene expression.
(See figure on previous page.)
Fig. 2 Focus networks between the primary atorvastatin target HMGCR and the transcription factors FoxA1, A2 and A3 of patient 65. Time course
of patient 65 is shown at 6 h (a), 12 h (b), 24 h (c), 48 h (d) and 72 h (e). The focus networks were created using viPEr, with a maximal path length
of 2 without considering the log2fold change: this allows direct comparison of time-course data. Up regulated nodes are shown as upward triangles,
colored in red. Down regulated nodes are displayed as downward arrows, colored green. The Fox transcription factors are colored orange, as is the
HMGCR. Protein-protein interactions have grey edges; edges of transcription factor gene interactions are colored red
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Many of the transcription factors that were present in
the HMGCR-FoxA1/2/3 focus network are also present
in the neighbor focus networks of the six patients. In all
networks, Sp1 seems to be a central hub. The atorva-
statin targets Ccl2 and Cyp3A4 are present in all but
one network (Patient 80), while HMGCR is not found in
any network. Note also that in Patient 79, most of the
genes are down-regulated, including the transcriptional
regulators Tp53 and Fos. Finally, we noticed that most
nodes that are shared between all patients are linker
nodes and thus not differentially expressed. Exceptions
thereof are Sp1, Fos and Tp53, all of which show differ-
ential expression in at least one sample.
We decided to cluster the patient data based on the
differential regulation and presence or absence of
nodes in the FoxA1 neighbor focus network using
Cluster3 [32]. The differential behavior of patient 67
is reflected in the resulting hierarchical tree (Additional
file 4: Figure S3 a, data available in Additional file 1:
Table S12). Furthermore, we observe a close cluster-
ing of patients 80 and 81, as well as a sub-group
formed by patients 79, 65 and 62. We were inter-
ested, if the same groups would cluster at the 24 h
time point in overall gene expression as well. We
therefore used the expression values of the probe IDs
at 24h (Additional file 1: Table S1) for cluster3 ana-
lysis (Additional file 4: Figure S3 b). Indeed, the clus-
tering of all expression values is highly comparable;
however, at the level of all analyzed genes, patient 62
displays more similarity to patient 79 than 65 in this
small sub-group.
Comparison to previous analysis
We started with the same primary data, as well as clus-
tering technique as Schröder, et al. [20], resulting in
identical clusters of co-regulated genes. Yet, our ap-
proach has channeled the analysis of the data in a differ-
ent direction. In the previous study, enrichment analysis,
followed by Cis-regulatory module detection in combin-
ation with network analysis was done. This yielded a set
of transcription factors with a hypothetical function in
atorvastatin-induced gene regulation. Factors such as
Krüppel-like factors Klf4 and Klf11, hypoxia-inducible
factor 1 (Hif1A), Hnf4, the nuclear receptor RXR in
Fig. 3 Enriched pathways identified by PEANuT on HMGCR/FoxA
focus networks. Three pathways were chosen for display: the
Integrated Breast Cancer Pathway (a), the Prostate Cancer Pathway (b)
and the Metabolism of Lipids and Lipoproteins Pathway (c). Members of
the respective pathways are highlighted in yellow. Up regulated
nodes are shown as upward triangles, colored in red. Down
regulated nodes are displayed as downward arrows, colored
green. The Fox transcription factors are shown in orange, as is the
HMGCR. Protein-protein interactions have grey edges; edges of
transcription factor gene interactions are colored red
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Fig. 4 (See legend on next page.)
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combination with other nuclear receptors, nuclear re-
ceptors PPARA, NR1H2 and NR2C2, Sp3 and Sp1, as
well as Tgif1, Smad2 or Elf1 were found in [20]. In our
primary atorvastatin focus network, we also found the
transcription factors RXRB, Hnf4A, PPARA, NR2C2,
Sp1, Sp3 and Klf4. The corresponding pathways of
these transcription factors were likewise enriched (see
Additional file 1: Tables S8 and S9). In the second step,
however, we did not pursue any of the above factors or
pathways. We rather focused on the FoxA transcription
factors and their potential role in atorvastatin response.
Interestingly, we also found Sp1 as a major transcriptional
regulator in our focus networks. Sp1 is known to coordin-
ate expression together with both, RXR/RAR (see for in-
stance [50–53]), as well as the FoxA transcription factors
[54–56]. Both, Sp1, as well as the FoxA transcription fac-
tors are also known to regulate some direct atorvastatin
drug targets [36, 38, 39, 52, 53, 57].
viPEr was in this study used to point towards less well
known players in atorvastatin response. In fact, we see
the advantage of a plug-in such as viPEr in exploring
paths that are difficult to find otherwise. If used with
numerical values from experimental studies such as an
expression screen, it will open up new avenues for ex-
perimental research.
Conclusions
Here we present the Cytoscape plug-ins viPEr (virtual
pathway explorer) and PEANuT (pathway analysis and
enrichment tool). viPEr provides the possibility to navi-
gate large interaction networks by linking two nodes or
two groups of nodes with each other. It can be used to
identify potential links between processes or pathways.
viPEr furthermore enables users to explore the neighbor-
hood of a single node with respect to the (numerical)
quality of radiating paths. The Cytoscape plug-in
PEANuT identifies enriched pathways in a focus net-
work compared to a background network. We used
viPEr to create focus networks, as well as neighbor focus
networks using time-series data on atorvastatin-treated,
primary hepatocytes from six donors. The focus network
was analyzed using PEANuT. We identified the FoxA1/
A2/A3 transcription factors to be involved in atorva-
statin response. Furthermore, PEANuT revealed that the
FoxA networks were enriched in cancer, as well as meta-
bolic pathways. We found interesting differences in
patient samples in the focus and neighbor focus net-
works, possibly explaining the often-observed, individual
responses to drug treatment.
While we used viPEr with numerical values from a
differential expression study, the plug-in can be used
with numbers inferred from any experimental set-up
and high-throughput assay. Functions ‘A to B’ and
‘connecting in batch’ work also without numerical
values to create focus networks. In this case, no scor-
ing of paths is done. The ‘environment search’, how-
ever, requires numerical values for the creation of a
neighbor focus network.
Availability and requirements
viPEr and PEANuT are all available via sourceforge.org.
Both plug-ins have been tested for the versions 2.8.2 and
2.8.3 of Cytoscape. Versions of viPEr and PEANuT are
also available for Cytoscape 3.2 and higher (viPEr for
Cytoscape version 3 is available via http://sourceforge.net/
projects/viperplugin/ and PEANuT for Cytoscape 3.2 and
higher is available via http://sourceforge.net/projects/
peanutv3/; for both apps, the source code is also
available via sourceforge.net and both apps will be re-
leased via the Cytoscape 3 app manager). Please note that
the current version of PEANuT v3 does not work with
Cytoscape versions below 3.0 or 3.1. viPEr and PEANuT
are fully integrated in both Cytoscape versions and com-
patible with other Cytoscape plug-ins. viPEr and PEANuT
will be maintained to work with future releases of
Cytoscape, as well as updates of public pathway database.
The required amount of memory depends mainly on
the background network. In general, we advise to have at
least 8 GB of RAM for the mouse or human interactome.
We furthermore advise to work with turned-off view of
large background networks (using the built-in Cytoscape
function ‘destroy view’). Cytoscape itself is written in Java
and runs on Linux, MacOS and Windows systems. We
advise to use Oracle Java, as we have not extensively tested
and validated our software for Open JDK.
Additional files
Additional file 1: Table S1. log2 fold change of six selected patients at
time points 6 h, 12 h, 24 h, 48 h and 72 h. Data were taken from [20],
Affymetrix probe IDs are shown. Table S2. Time-course and patient-
dependent clustering of probeIDs that showed differential expression in
(See figure on previous page.)
Fig. 4 Neighbor focus networks of FoxA1 in all six patients at 24 h. We chose to explore the environment of FoxA1 with respect to differential
expression. FoxA1 neighbor focus networks were created for patients 62 (a), 65 (b), 67 (c), 79 (d), 80 (e) and 81 (f). Up regulated nodes are shown
as upward triangles, colored in red. Down regulated nodes are displayed as downward arrows, colored green. The Fox transcription factors are
shown in orange, targets of atorvastatin are highlighted in cyan. Protein-protein interactions have grey edges; edges of transcription factor gene
interactions are colored red
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at least one time point or patient. 24 clusters were created using EDISA
3D clustering, containing 823 non-redundant, and differentially expressed
genes. Table S3. Annotation of the EDISA 3D-selected, differentially
expressed set of Affymetrix probe IDs. Table S4. GO enrichment of
EDISA 3D-selected, differentially expressed set of Affymetrix probe IDs.
Table S5. Pathway enrichment of EDISA 3D-selected, differentially
expressed set of Affymetrix probe IDs. Table S6. Targets of atorvastatin
as identified by STITCH. Table S7. GO enrichment of the atorvastatin
focus network. Table S8. Pathway enrichment of atorvastatin focus network
using PEANuT. Table S9. Pathway enrichment of the atorvastatin
focus network using DAVID. Table S10. Pathway enrichment of the
FoxA1/A2/A3 – HMGCR neighbor focus network using PEANuT. Table S11.
Pathway enrichment of the FoxA1/A2/A3 – HMGCR neighbor focus network
using DAVID. Table S12. Node scores for FoxA1 neighbor focus networks of
the six patients used for clustering. (XLSX 5773 kb)
Additional file 2: Figure S1. Focus network of all atorvastatin targets
and differentially expressed genes after EDISA 3D clustering (see text). Up
regulated nodes are shown as upward triangles, colored in red. Down
regulated nodes are displayed as downward arrows, colored green.
Protein-protein interactions have grey edges; edges of transcription factor
gene interactions are colored red. (PDF 489 kb)
Additional file 3: Figure S2. Focus networks of HMGCR and FoxA1/A2/
A3 of the six patients. Differential expression of nodes at 12 h is highlighted.
Data are shown for patients 62 (a), 65 (b), 67 (c), 79 (d), 80 (e) and 81 (f). Up
regulated nodes are shown as upward triangles, colored in red. Down
regulated nodes are displayed as downward arrows, colored green.
The Fox transcription factors are shown in orange, as is the HMGCR.
Protein-protein interactions have grey edges; edges of transcription
factor gene interactions are colored red. (PDF 160 kb)
Additional file 4: Figure 3. (a) Clustering of patients based on the
FoxA1 neighbor focus network shown in Fig. 4, as well as the probe ID
data from all patients at 24 h (b), data were taken from Additional file 1:
Table S1. (PDF 75 kb)
Abbreviations
PPI: Protein-Protein interaction; TFGI: Transcription Factor-Gene Interaction;
HMGCR: HMG-CoA (3-hydroxy-3-methylglutaryl–coenzyme A) reductase.
Competing interests
The authors declare that no competing interests exist.
Authors’ contributions
MG conceived and implemented the software viPEr, constructed the
interaction networks, analyzed the data and helped in writing this
manuscript. FH conceived and implemented PEANuT and helped in
writing this manuscript. VS ported PEANuT to Cytoscape Version 3,
tested PEANuT for Cytoscape versions 2 and 3, and helped with coding
the Cytoscape 3 version of viPEr. MT and BAK participated in data
evaluation and helped with strategy discussion; BHH conceived and
supervised this study, assisted in data analysis and wrote this
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Assa Yeroslaviz and Caroline Merhag for critical input to
viPEr, Michael Volkmer and Jose Villaveces for help in programming, and
Frank Schnorrer for critical reading of the manuscript. MG was funded by
BMBF grant 315737 the Virtual Liver Network (http://www.virtual-liver.de/);
FH was funded by BMBF grant 0315893B, SyBACol (http://www.sybacol.org/).
MT and BAK were supported by BMBF grant 315755 the Virtual Liver Network
(http://www.virtual-liver.de/) and by the Robert Bosch Foundation, Stuttgart,
Germany. We thank the Max Planck Society for supporting this work.
Author details
1CECAD Research Center, Joseph-Stelzmann-Str. 26, 50931 Cologne,
Germany. 2Gregor Mendel Institute of Molecular Plant Biology, Austrian
Acacdemy of Sciences, Vienna Biocenter (VBC), Dr. Bohr-Gasse 3, 1030
Vienna, Austria. 3Dr. Margarete Fischer-Bosch Institute of Clinical
Pharmacology and University of Tübingen, Auerbachstr. 112, 70376 Stuttgart,
Germany. 4Research Group Computational Biology, Max Planck Institute of
Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany. 5Present
address: Pensoft Publisher, 1700 Sofia, Bulgaria. 6Present address: Hain
Lifescience GmbH, Hardwiesenstr. 1, 72147 Nehren, Germany.
Received: 9 February 2015 Accepted: 8 October 2015
References
1. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, et al.
STRING 8–a global view on proteins and their functional interactions in
630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412–6.
2. Cerami E, Demir E, Schultz N, Taylor BS, Sander C. Automated network
analysis identifies core pathways in glioblastoma. PLoS One. 2010;5:e8918.
3. Dijkstra EW. A note on two problems in connexion with graphs. Numerische
Mathematik. 1959;1:269–71.
4. Bebek G, Yang J. PathFinder: mining signal transduction pathway segments
from protein-protein interaction networks. BMC Bioinformatics. 2007;8:335.
5. Stein LD. Using the Reactome database. Curr Protoc Bioinformatics.
2004;Chapter 8:Unit 8.7–8.7.16.
6. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al.
Gene ontology: tool for the unification of biology. The Gene Ontology
Consortium. Nat Genet. 2000;25:25–9.
7. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors
of HMG-CoA reductase. Pharmacol Res. 1995;31:9–27.
8. Mammen AL, Amato AA. Statin myopathy: a review of recent progress.
Curr Opin Rheumatol. 2010;22:644–50.
9. Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S. The
controversies of statin therapy: weighing the evidence. J Am Coll Cardiol.
2012;60:875–81.
10. Merli M, Bragazzi MC, Giubilo F, Callea F, Attili AF, Alvaro D. Atorvastatin-
induced prolonged cholestasis with bile duct damage. Clin Drug Investig.
2010;30:205–9.
11. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW.
Cognitive impairment associated with atorvastatin and simvastatin.
Pharmacotherapy. 2003;23:1663–7.
12. Howe K, Sanat F, Thumser AE, Coleman T, Plant N. The statin class of
HMG-CoA reductase inhibitors demonstrate differential activation of the
nuclear receptors PXR, CAR and FXR, as well as their downstream
target genes. Xenobiotica. 2011;41:519–29.
13. Rodrigues Díez R, Rodrigues-Díez R, Lavoz C, Rayego-Mateos S, Civantos E,
Rodríguez-Vita J, et al. Statins inhibit angiotensin II/Smad pathway and
related vascular fibrosis, by a TGF-β-independent process. PLoS One.
2010;5:e14145.
14. Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. JAK2-V617F-
mediated signalling is dependent on lipid rafts and statins inhibit JAK2-
V617F-dependent cell growth. Br J Haematol. 2013;160:177–87.
15. Lee H-Y, Youn S-W, Cho H-J, Kwon Y-W, Lee S-W, Kim S-J, et al. FOXO1
impairs whereas statin protects endothelial function in diabetes through
reciprocal regulation of Kruppel-like factor 2. Cardiovasc Res. 2013;97:143–52.
16. Ekström L, Johansson M, Monostory K, Rundlöf A-K, Arnér ESJ, Björkhem-
Bergman L. Simvastatin inhibits the core promoter of the TXNRD1 gene and
lowers cellular TrxR activity in HepG2 cells. Biochem Biophys Res Commun.
2013;430:90–4.
17. Leszczynska A, Gora M, Plochocka D, Hoser G, Szkopinska A, Koblowska M,
et al. Different statins produce highly divergent changes in gene expression
profiles of human hepatoma cells: a pilot study. Acta Biochim Pol.
2011;58:635–9.
18. Medina MW, Theusch E, Naidoo D, Bauzon F, Stevens K, Mangravite LM, et
al. RHOA is a modulator of the cholesterol-lowering effects of statin.
PLoS Genet. 2012;8:e1003058.
19. Hafner M, Juvan P, Rezen T, Monostory K, Pascussi J-M, Rozman D. The
human primary hepatocyte transcriptome reveals novel insights into
atorvastatin and rosuvastatin action. Pharmacogenet Genomics.
2011;21:741–50.
20. Schröder A, Wollnik J, Wrzodek C, Dräger A, Bonin M, Burk O, et al. Inferring
statin-induced gene regulatory relationships in primary human hepatocytes.
Bioinformatics. 2011;27:2473–7.
21. Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von Mering C, Jensen LJ,
et al. STITCH 2: an interaction network database for small molecules and
proteins. Nucleic Acids Res. 2010;38(Database issue):D552–6.
Garmhausen et al. BMC Genomics  (2015) 16:790 Page 12 of 13
22. Kamburov A, Wierling C, Lehrach H, Herwig R. ConsensusPathDB–a
database for integrating human functional interaction networks. Nucleic
Acids Res. 2009;37(Database issue):D623–8.
23. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, et al.
Pathway Commons, a web resource for biological pathway data. Nucleic
Acids Res. 2011;39(Database issue):D685–90.
24. WikiPathways. Pathway editing for the people. PLoS Biol. 2008;6:e184.
25. van Iersel MP, Pico AR, Kelder T, Gao J, Ho I, Hanspers K, et al. The BridgeDb
framework: standardized access to gene, protein and metabolite identifier
mapping services. BMC Bioinformatics. 2010;11:5.
26. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, de Bono B,
et al. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res.
2005;33(Database issue):D428–32.
27. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration
and interpretation of large-scale molecular data sets. Nucleic Acids Res.
2012;40(Database issue):D109–14.
28. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc.
1961;56:52–64.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Royal Stat Soc Ser B
(Methodological). 1995;57:289–300.
30. NCBI Resource Coordinators. Database resources of the National Center for
Biotechnology Information. Nucleic Acids Res. 2014;42(Database issue):D7–17.
31. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources. Nat Protoc.
2009;4:44–57.
32. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of
genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863–8.
33. Supper J, Strauch M, Wanke D, Harter K, Zell A. EDISA: extracting biclusters
from multiple time-series of gene expression profiles. BMC Bioinformatics.
2007;8:334.
34. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID:
the Pathway Interaction Database. Nucleic Acids Res. 2009;37(Database
issue):D674–9.
35. Friedman JR, Kaestner KH. The Foxa family of transcription factors in
development and metabolism. Cell Mol Life Sci. 2006;63:2317–28.
36. Antes TJ, Levy-Wilson B. HNF-3 beta, C/EBP beta, and HNF-4 act in synergy
to enhance transcription of the human apolipoprotein B gene in intestinal
cells. DNA Cell Biol. 2001;20:67–74.
37. Moya M, Benet M, Guzmán C, Tolosa L, García-Monzón C, Pareja E, et al.
Foxa1 reduces lipid accumulation in human hepatocytes and is down-
regulated in nonalcoholic fatty liver. PLoS One. 2012;7:e30014.
38. Paulweber B, Sandhofer F, Levy-Wilson B. The mechanism by which the
human apolipoprotein B gene reducer operates involves blocking of
transcriptional activation by hepatocyte nuclear factor 3. Mol Cell Biol.
1993;13:1534–46.
39. Rodríguez-Antona C, Bort R, Jover R, Tindberg N, Ingelman-Sundberg M,
Gómez-Lechón MJ, et al. Transcriptional regulation of human CYP3A4 basal
expression by CCAAT enhancer-binding protein alpha and hepatocyte
nuclear factor-3 gamma. Mol Pharmacol. 2003;63:1180–9.
40. Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E. Statin use and
breast cancer survival: a nationwide cohort study from Finland. PLoS One.
2014;9:e110231.
41. Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate
pathway. Curr Cancer Drug Targets. 2006;6:15–37.
42. Katz MS. Therapy insight: Potential of statins for cancer chemoprevention
and therapy. Nat Clin Pract Oncol. 2005;2:82–9.
43. Vemana G, Hamilton RJ, Andriole GL, Freedland SJ. Chemoprevention of
prostate cancer. Annu Rev Med. 2014;65:111–23.
44. Demierre M-F, Higgins PDR, Gruber SB, Hawk E, Lippman SM. Statins and
cancer prevention. Nat Rev Cancer. 2005;5:930–42.
45. Song L, Wei X, Zhang B, Luo X, Liu J, Feng Y, et al. Role of Foxa1 in
regulation of bcl2 expression during oxidative-stress-induced apoptosis in
A549 type II pneumocytes. Cell Stress Chaperones. 2009;14:417–25.
46. Wong WWL, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase
inhibitors and the malignant cell: the statin family of drugs as triggers of
tumor-specific apoptosis. Leukemia. 2002;16:508–19.
47. Wood WG, Igbavboa U, Muller WE, Eckert GP. Statins, Bcl-2, and apoptosis:
cell death or cell protection? Mol Neurobiol. 2013;48:308–14.
48. Moody SE, Schinzel AC, Singh S, Izzo F, Strickland MR, Luo L, et al. PRKACA
mediates resistance to HER2-targeted therapy in breast cancer cells and
restores anti-apoptotic signaling. Oncogene. 2015;34(16):2061–71.
49. Clendening JW, Pandyra A, Li Z, Boutros PC, Martirosyan A, Lehner R, et al.
Exploiting the mevalonate pathway to distinguish statin-sensitive multiple
myeloma. Blood. 2010;115:4787–97.
50. Ohoka Y, Yokota-Nakatsuma A, Maeda N, Takeuchi H, Iwata M. Retinoic acid
and GM-CSF coordinately induce retinal dehydrogenase 2 (RALDH2)
expression through cooperation between the RAR/RXR complex and
Sp1 in dendritic cells. PLoS One. 2014;9:e96512.
51. Cheng Y-H, Yin P, Xue Q, Yilmaz B, Dawson MI, Bulun SE. Retinoic acid (RA)
regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in
endometrium: interaction of RA receptors with specificity protein (SP) 1/SP3
for estradiol metabolism. J Clin Endocrinol Metab. 2008;93:1915–23.
52. Shimada J, Suzuki Y, Kim SJ, Wang PC, Matsumura M, Kojima S.
Transactivation via RAR/RXR-Sp1 interaction: characterization of binding
between Sp1 and GC box motif. Mol Endocrinol. 2001;15:1677–92.
53. Zannis VI, Kan HY, Kritis A, Zanni E, Kardassis D. Transcriptional regulation of
the human apolipoprotein genes. Front Biosci. 2001;6:D456–504.
54. Convertini P, Infantino V, Bisaccia F, Palmieri F, Iacobazzi V. Role of FOXA
and Sp1 in mitochondrial acylcarnitine carrier gene expression in different
cell lines. Biochem Biophys Res Commun. 2011;404:376–81.
55. Tatewaki H, Tsuda H, Kanaji T, Yokoyama K, Hamasaki N. Characterization of
the human protein S gene promoter: a possible role of transcription factors
Sp1 and HNF3 in liver. Thromb Haemost. 2003;90:1029–39.
56. Ceelie H, Spaargaren-Van Riel CC, De Jong M, Bertina RM, Vos HL. Functional
characterization of transcription factor binding sites for HNF1-alpha, HNF3-beta
(FOXA2), HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer.
J Thromb Haemost. 2003;1:1688–98.
57. Bombail V, Taylor K, Gibson GG, Plant N. Role of Sp1, C/EBP alpha, HNF3,
and PXR in the basal- and xenobiotic-mediated regulation of the CYP3A4
gene. Drug Metab Dispos. 2004;32:525–35.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Garmhausen et al. BMC Genomics  (2015) 16:790 Page 13 of 13
